We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Addex Appoints Dr. Graham Dixon as Chief Scientific Officer and Head of Research
News

Addex Appoints Dr. Graham Dixon as Chief Scientific Officer and Head of Research

Addex Appoints Dr. Graham Dixon as Chief Scientific Officer and Head of Research
News

Addex Appoints Dr. Graham Dixon as Chief Scientific Officer and Head of Research

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Addex Appoints Dr. Graham Dixon as Chief Scientific Officer and Head of Research"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

"We are delighted to have Graham join the Addex team. Graham has a strong background and an impressive track record in small molecule pharmaceutical research and development. He has been responsible for the discovery of novel drugs and steering their development from basic science into clinical development, as well as bringing products through mid-stage proof-of-concept clinical trials." stated Dr. Bharat Chowrira, CEO of Addex. "Addex' strength lies in our leading allosteric modulation technology and the ability to leverage this platform to develop drug candidates against previously undruggable but important validated biological targets. Graham's experience and R&D leadership will be instrumental as we execute on our core strategy and continue to build a robust proprietary pipeline of high value drug discovery and development programs and rapidly advancing these drug candidates towards the clinic"

Dr. Dixon joins Addex with more than 20 years of experience in pharmaceutical researc, most recently as Chief Scientific Officer at Galapagos NV. In this role, Dr. Dixon was responsible for all research & early development within the company in multiple therapeutic areas as well as the management of more than 260 scientific personnel across three sites in the Netherlands, Belgium and France. Prior to Galapagos, Dr. Dixon was Chief Scientific Officer at Entomed SA, a developer of natural anticancer and anti-infective agents. Dr. Dixon joined Entomed from a similar role at antifungal therapeutic company, F2G Ltd. Before joining F2G, Dr. Dixon held several roles at AstraZeneca starting as a project manager in anti-infective research and culminating in the role of Global Product Director in the oncology division. He started his career as Head of Biochemistry at Dowelanco (UK) Ltd. Dr. Dixon earned his PhD in biochemistry from the University of Swansea and a BSc in applied biology from the University of Bradford.

"I am excited about joining Addex, the recognized industry leader in allosteric modulation-based oral small molecule drug discovery and development," said Dr. Dixon. "I look forward to building on the significant progress made by the world-class scientists at Addex and applying this powerful platform towards creating an attractive engine of innovative product candidates for the treatment of serious diseases and indications with a huge unmet medical need."

Advertisement